乳腺多参数18F-FDG PET/MRI:良恶性肿瘤患者对侧健康组织影像生物标志物差异
该前瞻性单中心研究纳入141例乳腺影像异常(BI-RADS 4/5)女性,行3T 18F-FDG PET/MRI(动态增强、弥散加权及18F-FDG),评估对侧无瘤乳腺的BPU、ADC、BPE及FGT。结果显示恶性与良性病变患者的对侧BPE和BPU存在显著差异(P<0.001),FGT接近但未达显著(P=0.055),ADC无差异(P=0.19)。
要点
- 乳腺癌患者对侧无瘤乳腺BPE较良性病变患者显著降低(P<0.001)。
- BPU在良恶性组间差异显著(均值1.9 vs 1.8,P<0.001)。
- 对侧BPE、BPU和FGT降低或可提示恶性肿瘤存在。
核心结论
- 良恶性乳腺肿瘤患者对侧无瘤乳腺的多参数18F-FDG PET/MRI生物标志物存在差异。
- 对侧BPE、BPU和FGT在乳腺癌患者中降低,可能作为恶性肿瘤存在的影像生物标志物。
研究设计与样本
- 机构审查委员会批准的前瞻性单中心研究,纳入141例乳腺影像异常(BI-RADS 4/5)女性。
- 所有患者接受3T 18F-FDG PET/MRI,包括动态增强MRI、弥散加权成像和18F-FDG示踪剂。
- 对侧无瘤乳腺记录BPU、平均ADC、BPE和FGT,比较良恶性病变组间差异。
主要发现
- 共100个恶性病变和41个良性病变。
- BPE分布:61例轻微、56例轻度、19例中度、5例显著。
- BPE在良恶性组间差异显著(P<0.001),癌症患者对侧无瘤乳腺BPE降低。
- FGT接近但未达显著性(P=0.055)。
- BPU在良性病变组均值1.9,恶性病变组均值1.8,差异显著(P<0.001);平均ADC组间无差异(P=0.19)。
关键数值与推荐
- BPE分级:轻微61例、轻度56例、中度19例、显著5例。
- BPU按BPE分级:轻微1.5、轻度1.9、中度2.2、显著1.9。
- 良性病变组BPU均值1.9,恶性病变组均值1.8(P<0.001)。
- BPE组间比较P<0.001;FGT组间比较P=0.055;平均ADC组间比较P=0.19。
临床怎么用
- 对乳腺影像异常(BI-RADS 4/5)患者,可评估对侧无瘤乳腺的BPE、BPU和FGT作为潜在恶性提示标志。
- 多参数18F-FDG PET/MRI可提供对侧乳腺组织影像生物标志物信息,辅助风险判断。
局限性
- 单中心前瞻性研究,样本为影像异常(BI-RADS 4/5)女性。
- FGT组间差异未达统计学显著性(P=0.055)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The rationale was to assess whether there are differences in multiparametric 18F-FDG PET/MRI biomarkers of contralateral healthy breast tissue in patients with benign and malignant breast tumors. Methods: In this institutional review board-approved prospective single-institution study, 141 women with imaging abnormalities on mammography or sonography (BI-RADS 4/5) underwent combined 18F-FDG PET/MRI of the breast at 3T with dynamic contrast-enhanced MRI, diffusion-weighted imaging, and the radiotracer 18F-FDG. In all patients, the following imaging biomarkers were recorded for the contralateral (tumor-free) breast: breast parenchymal uptake (BPU) (from 18F-FDG PET), mean apparent diffusion coefficient (from diffusion-weighted imaging), background parenchymal enhancement (BPE), and amount of fibroglandular tissue (FGT) (from MRI). Appropriate statistical tests were used to assess differences in 18F-FDG PET/MRI biomarkers between patients with benign and malignant lesions. Results: There were 100 malignant and 41 benign lesions. BPE was minimal in 61 patients, mild in 56, moderate in 19, and marked in 5. BPE differed significantly (P < 0.001) between patients with benign and malignant lesions, with patients with cancer demonstrating decreased BPE in the contralateral tumor-free breast. FGT approached but did not reach significance (P = 0.055). BPU was 1.5 for patients with minimal BPE, 1.9 for mild BPE, 2.2 for moderate BPE, and 1.9 for marked BPE. BPU differed significantly between patients with benign lesions (mean, 1.9) and patients with malignant lesions (mean, 1.8) (P < 0.001). Mean apparent diffusion coefficient did not differ between groups (P = 0.19). Conclusion: Differences in multiparametric 18F-FDG PET/MRI biomarkers, obtained from contralateral tumor-free breast tissue, exist between patients with benign and patients with malignant breast tumors. Contralateral BPE, BPU, and FGT are decreased in breast cancer patients and may potentially serve as imaging biomarkers for the presence of malignancy.
引用
- Leithner D, Helbich TH, Bernard-Davila B, et al. Multiparametric 18F-FDG PET/MRI of the Breast: Are There Differences in Imaging Biomarkers of Contralateral Healthy Tissue Between Patients With and Without Breast Cancer? J Nucl Med. 2019. PMID: 31253745. doi:10.2967/jnumed.119.230003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。